The impact of different WHO reference criteria for semen analysis in clinical practice: Who will benefit from the new 2021 thresholds for normal semen parameters?

Luca Boeri¹ | Giuseppe Fallara² | Edoardo Pozzi² | Federico Belladelli² | Christian Corsini² | Massimiliano Raffo² | Nicolò Schifano² | Paolo Capogrosso³ | Alessia d’Arma² | Francesco Montorsi² | Andrea Salonia²

¹Department of Urology, Foundation IRCCS Ca’ Granda, Maggiore Policlinico Hospital, Milan, Italy
²Unit of Urology, Division of Experimental Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy
³Department of Urology and Andrology, Ospedale di Circolo and Macchi Foundation, Varese, Italy

Abstract

Background: In 2021, the World Health Organization (WHO) has provided the latest update on processing and evaluating semen analysis.

Objectives: To assess (i) the rate of discordance in semen parameters categorization across three different WHO reference values (namely WHO21, 2010 and 1999) and (ii) the clinical differences among discordant semen analyses from a cohort of primary infertile men.

Materials and methods: Data from 788 infertile men were analyzed. Semen parameters were interpreted based on WHO21, WHO10, and WHO99 reference criteria. Pregnancy outcomes with assisted reproductive techniques (ART) were available for 110 (14%) patients. Descriptive statistics was applied to describe potential differences among the three consecutive WHO references criteria.

Results: Semen parameters categorizations were highly different across the three groups (p < 0.001). Of all, 271 (42.2%) patients had normal semen parameters according to WHO10 but were pathologic when considered with WHO21 reference criteria (namely, men with increased semen abnormalities). Infertile men with increased semen abnormalities had lower testicular volume (p < 0.001) but higher FSH (p < 0.01) and LH (p < 0.001) values than those who had no change in terms of semen parameters categorization. Negative ART outcomes were more frequently reported in men with worsening semen parameters compared with those with confirmed semen parameters at WHO21 versus WHO10 (26.8% vs. 49%, p = 0.03). Conversely, infertile men with worsening semen parameters at WHO21 versus WHO99 were similar in terms of

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.
clinical and hormonal characteristics compared with those with the same rate of semen abnormalities.

**Conclusions:** One out of three infertile men showed worsened semen categorization according to WHO21 versus WHO10. Infertile men with worsening of semen parameters had worse clinical and hormonal characteristics than those with confirmed numbers of semen abnormalities. Moreover, live birth rates were lower in men with worsening semen abnormalities as for WHO21.

**KEYWORDS**
classification, male factor infertility, semen parameters, World Health Organization
RESULTS

Statistical methods

Distribution of data was tested graphically and with the Shapiro–Wilk test. Data are presented as medians (interquartile range; IQR) or frequencies (proportions). First, semen parameters were interpreted based on 2021 (WHO21), 2010 (WHO10), and 1999 (WHO99) WHO reference criteria and the rate of discordance in terms of semen abnormalities categorization among groups was investigated. Second, the Kruskal–Wallis test and the Fisher exact were used to investigate demographics, clinical and laboratory characteristics between men who showed increased semen abnormalities when considering WHO21 versus WHO10 and those who had no change in semen parameters categorization. Specifically, the newly proposed thresholds for semen abnormalities according to WHO21 identified a group of men who had normal semen parameters according to WHO10 but were pathologic when considered with WHO21 reference criteria (namely, men with increased semen abnormalities) (Figure 1).

Similarly, we applied descriptive statistics to compare clinical characteristics and laboratory values between participants who have depicted different types of semen worsening by using WHO21 reference criteria compared with those with no change in semen categorization (Figure 2). Third, we tested the potential difference of clinical characteristics between men who showed increased semen abnormalities when considering WHO99 versus WHO21 and those who had no change in semen parameters categorization. Statistical analyses were performed using SPSS v.26 (IBM Corp., Armonk, NY, USA). All tests were pathologic when considered with WHO21 reference criteria (namely, men with increased semen abnormalities) (Figure 1).

3 | RESULTS

Table 1 details the reference values for semen parameters according to different editions of the WHO Manual for the Examination and Processing of Human Semen. Moreover, the prevalence of semen abnormalities according to different reference values in the whole cohort was also reported.

Semen parameters categorizations were highly different across the three groups (p < 0.001) (Figure 3). Overall, normozoospermia was found in 31 (3.9%), 138 (17.5%), and 126 (16.0%) patients according to WHO99, WHO10, and WHO21, respectively (p < 0.001). Similarly, oligoasthenoteratozoospermia was reported in 247 (31.3%), 146 (18.5%), and 167 (21.2%) men according to WHO99, WHO10, and WHO21, respectively (p < 0.001).

Of 788, 271 (34.4%) men had increased semen abnormalities when considering WHO21 versus WHO10.

Tables 2 and 3 report descriptive statistics of participants who had increased semen abnormalities by WHO21 compared with those
whose semen parameters did not change. Infertile men with increased semen abnormalities had lower TV ($p < 0.001$), higher FSH and LH values (all $p \leq 0.01$) than those who did not depict change in semen parameters categorization. A higher rate of genetic alterations (any type) was found in men with worsening semen categorization ($p = 0.02$) (Table 3). Of note, SDF was higher ($p < 0.001$) in men with worsening of their categorization according to WHO21 versus WHO10. Likewise, a greater prevalence of men had SDF > 30% after worsening of semen parameters categorization at WHO21 compared with WHO10 ($p < 0.001$). Of note, we found that 12.3% versus 11.9% ($p = 0.6$) men with unexplained infertility had abnormal SDF by WHO10 and WHO21, respectively.

Negative ART outcomes were more frequently reported in men with worsening semen parameters than those with confirmed semen parameters categorization at WHO21 versus WHO10 ($p = 0.03$) (Table 3).

Supplementary Tables 1 and 2 depict clinical characteristics of participants according to different type of semen parameters categorization. In this context, patients with 2 semen abnormalities at WHO10 that increased to 3 semen abnormalities at WHO21 showed lower TV ($p < 0.01$), but higher FSH values ($p = 0.03$) and SDF ($p = 0.03$) than those with 2 semen abnormalities both at WHO21 and WHO10. Of note, clinical characteristics of men who increased from 2 to 3 semen abnormalities were similar to those of men with confirmed 3 abnormalities at both editions of the manual.

No differences were found among men who had increased from 1 to 2 semen abnormalities at WHO21 versus WHO10 compared with those with confirmed either 1 or 2 semen abnormalities at both
editions. Similarly, infertile men with worsening semen parameters categorization by using WHO99 versus WHO21 depicted similar clinical, hormonal and SDF characteristics compared with those with the same rate of semen abnormalities at both editions.

4 | DISCUSSION

Semen analysis is the backbone of the diagnostic work-up of each infertile male.1,7 Thereof, decision making for the clinical management of MFI is often based on semen quality and the severity of semen abnormalities.1 Recently, the 2021 edition of the WHO manual for the examination of semen samples has proposed new reference values for semen abnormalities that differed from those of the latest 2010 edition.11 To the best of our knowledge an explorative investigation of the clinical impact of this change in terms of reference values of semen parameters is currently lacking.

Here, we found that one out of three infertile men showed increased severity of sperm categorization according to WHO21 versus WHO10, thus meaning that semen parameters were above the reference limit for normality according to WHO10 while they have been categorized as pathologic according to the new WHO21 reference limits. Infertile men with worsening sperm categorization had worse clinical, hormonal, and reproductive parameters as compared with those without changes in semen abnormalities rates. Conversely, this difference was not found when considering WHO99 versus WHO21 reference criteria. Taking together, these findings would suggest that the WHO21 criteria better identify a subgroup of patients with impaired reproductive health despite being considered with normal semen parameters according to WHO10 reference criteria.

It is well known that there is a substantial intersection of semen quality between fertile and subfertile men, and there are no distinct confines between fertile versus infertile men only relying on semen parameters at semen analysis.10,11 Nonetheless, semen quality is used in clinical practice to tailor the management work-up in men presenting for couple’s infertility.7 For instance, the American Urological Association/American Society for Reproductive Medicine (AUA/ASRM) Guidelines for the diagnosis and treatment of MFI suggest obtaining hormonal evaluation in men with impaired libido, erectile dysfunction, oligozoospermia, or azoospermia.6,29 Likewise, genetic testing is advise by the AUA/ASRM and EAU Guidelines in azoospermic men or in infertile men with severe oligozoospermia.1,6 In terms of MFI treatment, the use of gonadotropins is considered in men with idiopathic oligozoospermia and FSH values within the normal range to improve spermatogenic outcome.1,7 Lastly, the treatment of clinical varicocele has been suggested in men with abnormal semen parameters and
| TABLE 2  Descriptive statistics of participants as segregated according to worsening semen categorization by using WHO21 versus WHO10 reference criteria (no. = 642*) |
|-----------------------------------------------|
| Overall | No change in semen abnormalities | Increased number of semen abnormalities | p Value§ |
| No. of patients (no. [%]) | 642 (100) | 371 (57.8) | 271 (42.2) | 0.2 |
| Age (years) | | | | |
| Median (IQR) | 37.0 (33–41) | 36.0 (33–40) | 37.0 (33–41) | |
| Range | 20–50 | 20–50 | 20–50 | 0.5 |
| BMI (kg/m²) | | | | |
| Median (IQR) | 24.8 (23.1–26.7) | 24.7 (23.1–26.5) | 24.9 (23.1–26.7) | 0.9 |
| Range | 19.9–41.2 | 20.0–37.6 | 19.9–41.2 | |
| CCI (value) | | | | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.3 |
| Mean (SD) | 0.08 (0.4) | 0.09 (0.4) | 0.07 (0.5) | |
| Range | 0–3 | 0–3 | 0–3 | |
| CCI ≥1 (no. [%]) | 14 (2.1) | 7 (1.8) | 7 (2.5) | 0.4 |
| Partner’s age (years) | | | | |
| Median (IQR) | 34.0 (32–38) | 34.0 (32–38) | 34.0 (31–38) | 0.5 |
| Range | 20.0–48.0 | 20.0–48.0 | 20.0–47.0 | |
| Duration of infertility (months) | | | | |
| Median (IQR) | 18.0 (12–30) | 18.0 (12–26) | 19.0 (12–30) | 0.2 |
| Range | 12.0–60.0 | 12.0–60.0 | 12.0–58.0 | |
| Testis volume (Prader estimation) | | | | |
| Median (IQR) | 18.0 (14–20) | 20.0 (15–25) | 15.0 (12–20) | <0.001 |
| Range | 6–25 | 6–25 | 6–25 | |
| Clinical varicocele (no. [%]) | 364 (56.6) | 207 (55.8) | 157 (57.9) | 0.6 |
| History of cryptorchidism (no. [%]) | 55 (8.5) | 28 (7.6) | 27 (10.3) | 0.2 |
| Genetic alterations (any type) (no. [%]) | 47 (7.3) | 20 (5.4) | 27 (10.0) | 0.02 |
| Current smoking status (no. [%]) | 211 (32.8) | 121 (32.7) | 90 (33.4) | 0.5 |

*After excluding 146 participants that showed 3 semen abnormalities according to both WHO10 and WHO21.
§p Value according to the Mann–Whitney test for continuous data and the Fisher exact test for categorical variables, as indicated.
Abbreviations: BMI = body mass index; CCI = Charlson Comorbidity Index.

otherwise unexplained infertility,1,7 thus highlighting the importance of reference values for considering normal versus impaired semen quality in the everyday clinical practice.

Of clinical importance, the severity of semen abnormalities has been associated with health outcomes in infertile men. Indeed, previous studies have shown that semen parameters were inversely associated with the overall burden of comorbid conditions in infertile men23,30,31; similarly, a recent study with 1957 infertile men showed that CCI progressively increased along with the number of semen alterations.10 In this context MFI can be considered as a proxy of overall men's health.32,33

From a clinical standpoint, semen quality has been associated with the clinical and hormonal profile of infertile men. Boeri et al., for instance, showed that clinical characteristics and hormonal parameters of infertile men got worse as the number of semen alterations increased.30 Moreover, TV has been considered a good clinical marker of reproductive function and previous studies have reported the association between a reduced TV and poor semen parameters.10 In terms of reproductive outcomes, SDF testing has progressively emerged as an important tool for the clinical management of MFI.34,35 Several conditions have been associated with increasing SDF in infertile men, thus including recreational habits, environmental toxins, varicocoele, and genital infections35,36; however, the correlation between SDF with semen quality by routine semen analysis is still a matter of debate. In fact, some studies have reported a negative correlation between SDF and semen parameters,37,38 but this was not the case for other reports.39 Our results are concordant with these findings; indeed, we showed that infertile men with worsening semen parameters categorization had lower TV and higher FSH values than those with confirmed semen abnormalities as for WHO21 and WHO10, respectively. Moreover, SDF and live birth rates were lower in men with worsening semen categorization. In particular, we found that infertile men with 2 semen
|                                | Overall                      | No change in semen abnormalities | Increased number of semen abnormalities | \( p \) Value$^\dagger$ |
|--------------------------------|------------------------------|----------------------------------|----------------------------------------|--------------------------|
| **FSH (mUI/ml)**               |                              |                                  |                                        | <0.001                   |
| Median (IQR)                   | 4.3 (2.9–7.1)                | 3.7 (2.7–6.0)                    | 5.0 (3.4–9.1)                          |                          |
| Range                          | 0.6–32.7                     | 0.6–21.8                         | 0.7–32.7                               |                          |
| **LH (mUI/ml)**                |                              |                                  |                                        | <0.001                   |
| Median (IQR)                   | 3.8 (2.7–5.1)                | 3.6 (2.4–4.7)                    | 4.2 (3.0–5.4)                          |                          |
| Range                          | 0.3–16.0                     | 0.3–13.3                         | 0.9–16.0                               |                          |
| Total testosterone (ng/ml)     |                              |                                  |                                        | 0.1                      |
| Median (IQR)                   | 4.7 (3.6–5.8)                | 4.8 (3.6–5.7)                    | 4.7 (3.5–5.9)                          |                          |
| Range                          | 0.9–20.6                     | 0.9–20.6                         | 1.2–15.5                               |                          |
| **SHBG (nmol/L)**              |                              |                                  |                                        | 0.3                      |
| Median (IQR)                   | 36.0 (27–45)                 | 35.0 (27.0–44.1)                 | 36.0 (27.6–46)                         |                          |
| Range                          | 7.5–154.0                    | 11.0–154.0                       | 7.5–135.0                              |                          |
| **E2 (pg/ml)**                 |                              |                                  |                                        | 0.6                      |
| Mean (SD)                      | 25.0 (27–45)                 | 25.0 (24–34)                     | 24.9 (21–38)                           |                          |
| Range                          | 1.0–89.6                     | 1.0–89.6                         | 2.2–78.2                               |                          |
| **Inhibin B (pg/ml)**          |                              |                                  |                                        | 0.02                     |
| Median (IQR)                   | 144.6 (104.1–205.8)          | 151.6 (115.8–211.7)              | 132.7 (78.6–195.7)                     |                          |
| Range                          | 5.2–671.3                    | 14.0–538.0                       | 5.2–671.3                              |                          |
| **Prolactin (ng/ml)**          |                              |                                  |                                        | 0.1                      |
| Median (IQR)                   | 8.5 (6.5–11.9)               | 8.2 (6.2–10.7)                   | 9.1 (6.8–12.4)                         |                          |
| Range                          | 1.9–67.7                     | 1.9–45.7                         | 2.1–67.7                               |                          |
| Semen volume (ml)              |                              |                                  |                                        | <0.001                   |
| Median (IQR)                   | 3.0 (2–4)                    | 3.0 (2–4)                        | 3.0 (2–4)                              |                          |
| Range                          | 0.9–10.0                     | 0.9–10.0                         | 0.5–9.0                                |                          |
| Sperm concentration \( \times 10^6/\text{ml} \) |                              |                                  |                                        | <0.001                   |
| Median (IQR)                   | 24.0 (8.5–50.0)              | 38.3 (20.0–65.1)                 | 9.0 (3.5–22.0)                         |                          |
| Range                          | 0.1–455.3                    | 0.5–455.3                        | 0.1–114.0                              |                          |
| Total motility (%)             |                              |                                  |                                        | <0.001                   |
| Median (IQR)                   | 50.0 (37–62)                 | 55.0 (46–67)                     | 40.0 (30–50)                           |                          |
| Range                          | 0.0–122.0                    | 0.0–122.0                        | 0.0–100.0                              |                          |
| Normal morphology (%)          |                              |                                  |                                        | <0.001                   |
| Median (IQR)                   | 3.0 (1–10)                   | 5.0 (2–14)                       | 2.0 (1–5)                              |                          |
| Range                          | 0.0–100.0                    | 0.0–94.0                         | 0.0–100.0                              |                          |
| **SDF (%)**                    | \( n = 270 \)                | \( n = 140 \)                    | \( n = 130 \)                          | <0.001                   |
| Median (IQR)                   | 25.7 (16.2–42.2)             | 23.0 (13.6–35.0)                 | 30.8 (19.3–49.7)                       |                          |
| Range                          | 0.4–96.4                     | 0.4–90.4                         | 1.5–96.4                               |                          |
| SDF > 30% (no. [%])            | 119 (44.1)                   | 44 (31.4)                        | 75 (56.9)                              | <0.001                   |
| Assisted-pregnancy rate (no. [%]) | 36 (39.1)               | 25 (49.0)                        | 11 (26.8)                              | 0.03                     |

Abbreviations: FSH = follicle stimulating hormone; LH = luteinizing hormone; SHBG = sex hormone binding globulin; E2 = estradiol; SDF = sperm DNA fragmentation index.

*After excluding 146 participants that showed 3 semen abnormalities according to both WHO10 and WHO21.

$^\dagger p$ Value according to the Mann–Whitney test for continuous data and the Fisher Exact Test for categorical variables, as indicated.
abnormalities at WHO10 who conversely increased to 3 semen abnormalities at WHO21, actually have clinical and hormonal characteristics similar to men with 3 semen abnormalities for both WHO editions and even worse parameters than those with only confirmed 2 semen abnormalities. These results suggest that the new reference values for semen quality proposed by WHO21 is able to even better identify, and actually categorize as having “pathologic” semen quality, a group of men with impaired clinical characteristics and reproductive parameters despite being considered with normal semen parameters according to WHO10 reference criteria. In light of the known association between semen quality and clinical features and health outcomes, the new classification is therefore more rigorous in recognizing infertile men with impaired semen and health parameters.

Our study is novel since we conducted the first real-life contemporary investigation of the rate of men with normal and abnormal semen parameters according to different reference values proposed by three WHO editions over a 20 years period in a homogenous, same-ethnicity, age-comparable cohort of infertile men. Second, we detailed the importance of the association between semen impairment and patient’s characteristics, thus highlighting the value of different reference values for semen analysis.

Likewise, our study is not devoid of limitations. First, this was a single center-based study, raising the possibility of selection biases; thereof, larger studies are needed to externally validate our findings. Second, despite our evaluation includes a comprehensive assessment of the whole cohort in terms of clinical, semen and hormonal evaluation, we lacked an oxidative stress investigation in the entire cohort of participants, which is known for its negative effect toward semen quality.40

5 | CONCLUSIONS

The recent introduction of new reference criteria for semen parameters by WHO21 resulted in a different categorization of severity of semen abnormalities as compared with both previous editions. Indeed, one out of three infertile men showed worsened semen categorization according to WHO21 versus WHO10. Infertile men with worsening semen parameters had worse clinical, hormonal and SDF characteristics than those with confirmed numbers of semen abnormalities. Moreover, pregnancy outcomes with assisted reproductive techniques were lower in men with worsening semen abnormalities as for WHO21. Overall, WHO21 criteria better identify a subgroup of patients with impaired reproductive health despite being considered with normal semen parameters according to WHO10. According to WHO21 reference criteria, semen quality ought to be considered as a continuum and the artificial binary division between “normal” and “abnormal” should be used cautiously and only considered as a rough guidance in clinical practice. Further studies are needed to externally confirm these observations.

CONFLICT OF INTERESTS

The authors have declared that no conflict of interest exists.

AUTHOR CONTRIBUTIONS

LB and AS designed and led the study and wrote the report. PC, GF, EP, FB, CC, MR, NS, AD, and FM took care of patients and acquired data. LB and AS analyzed data and drafted the report.

ORCID

Giuseppe Fallara https://orcid.org/0000-0001-7872-2650
Paolo Capogrosso https://orcid.org/0000-0003-2347-9504
Andrea Salonia https://orcid.org/0000-0002-0595-7165

REFERENCES

1. Minhas S, Bettocchi C, Boeri L, et al. European association of urology guidelines on male sexual and reproductive health: 2021 update on male infertility. Eur Urol. 2021;90(3):381-398.
2. Levine H, Jørgensen N, Martino-Andrade A, et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update. 2017;23(6):646-659.
3. Sengupta P, Borges E, Dutta S, Krajewska-Kulak E. Decline in sperm count in European men during the past 50 years. Hum Exp Toxicol. 2018;37(3):247-255.
4. Sunderam S, Kissin DM, Zhang Y, et al. Assisted reproductive technology surveillance—United States, 2017. MMWR Surveill Summ. 2020;69(9):1-20.
5. Salonia A, Matloob R, Saccà A, et al. Are Caucasian-European men delaying fatherhood? Results of a 7 year observational study of infertile couples with male factor infertility. Int J Androl. 2012;35(2):125-132.
6. Schlegel PN, Sigman M, Collura B, et al. Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. Fertil Steril. 2021;115(1):54-61.
7. Boeri L, Capogrosso P, Ortensi I, et al. Diagnostic and therapeutic workup of male infertility: results from a Delphi consensus panel. Int J Impot Res. 2021. Online ahead of print.
8. Pozzi E, Boeri L, Candela L, et al. Infertile couples still undergo assisted reproductive treatments without initial andrological evaluation in the real-life setting: a failure to adhere to guidelines? Andrologia. 2021;9(6):1843-1852.
9. Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010;16(3):231-245.
10. Boeri L, Belladelli F, Capogrosso P, et al. Normal sperm parameters per se do not reliably account for fertility: a case-control study in the real-life setting. Andrologia. 2021;53(1):13861.
11. Wang C, Mbizvo M, Festin MP, Björndahl L, Toskin I. Other editorial board members of the WHO laboratory manual for the examination and processing of human semen. Evolution of the WHO “Semen” processing manual from the first (1980) to the sixth edition (2021). Fertil Steril. 2022;S0015-0282(21):02246-02249.
12. Agarwal A, Bragais FM, Sabanegh E. Assessing sperm function. Urol Clin North Am. 2008;35(2):157-171. vii.
13. Boeri L, Ventimiglia E, Cazzaniga W, et al. Risk of health status worsening in primary infertile men: a prospective 10-year follow-up study. Andrologia. 2021;101(1):128-136.
14. Del Giudice F, Kasman AM, Ferro M, et al. Clinical correlation among male infertility and overall male health: a systematic review of the literature. Investag Clin Urol. 2020;61(4):355-371.
15. Del Giudice F, Kasman AM, Chen T, et al. The association between mortality and male infertility: systematic review and meta-analysis. Urolgy. 2021;154:148-157.
16. WHO laboratory manual for the examination and processing of human semen. Sixth edition. Available at: https://www.who.int/publications/i/item/9789240030787
17. Campbell MJ, Lotti F, Baldi E, et al. Distribution of semen examination results 2020—a follow up of data collated for the WHO semen analysis manual 2010. Andrology. 2021;9(3):817-822.
18. van der Steeg JW, Steures P, Eijkemans MJ, et al. Role of semen analysis in subfertile couples. Fertil Steril. 2011;95(3):1013-1019.
19. Colpi GM, Francavilla S, Haidl G, et al. European Academy of Andrology Guideline Management of oligo-astheno-teratozoospermia. Andrology. 2018;6(4):513-524.
20. World Health Organization. Infertility definitions and terminology. Accessible at: https://www.who.int/reproductivehealth/topics/infertility/definitions/en/, Accessed March 28, 2020.
21. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. Fertil Steril. 2021;116(5):1255-1265.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
23. Salonia A, Matloob R, Gallina A, et al. Are infertile men less healthy than fertile men? Results of a prospective case-control survey. Eur Urol. 2009;56(6):1025-1031.
24. Boeri L, Capogrosso P, Ventimiglia E, et al. Testicular volume in infertile men and alcohol consumption are associated with impaired sperm parameters in primary infertile men. Asian J Androl. 2019;21(5):501-509.
25. Boeri L, Capogrosso P, Ventimiglia E, et al. Heavy cigarette smoking and alcohol consumption are associated with impaired sperm parameters in primary infertile men. Asian J Androl. 2019;21(5):478-485.
26. Boeri L, Ventimiglia E, Capogrosso P, et al. The duration of infertility affects semen parameters in primary infertile men: results of a single-centre, cross-sectional study. BJIU Int. 2019;123(5):891-898.
27. Ventimiglia E, Capogrosso P, Boeri L, et al. When to perform Karyotype analysis in infertile men? Validation of the European Association of Urology guidelines with the proposal of a new predictive model. Eur Urol. 2016;70(6):920-923.
28. Evenson DP. Sperm chromatin structure assay (SCSA®). Methods Mol Biol. 2013;927:147-164.
29. Ventimiglia E, Capogrosso P, Boeri L, et al. Validation of the American Society for Reproductive Medicine guidelines/recommendations in white European men presenting for couple’s infertility. Fertil Steril. 2016;106(5):1076-1082.e1.
30. Ventimiglia E, Capogrosso P, Boeri L, et al. Infertility as a proxy of general male health: results of a cross-sectional survey. Fertil Steril. 2015;104(1):48-55.
31. Eisenberg ML, Li S, Behr B, Pera RR, Cullen MR. Relationship between semen production and medical comorbidity. Fertil Steril. 2015;103(1):66-71.
32. Capogrosso P, Ventimiglia E, Boeri L, et al. Male infertility as a proxy of the overall male health status. Minerva Urol Nefrol. 2018;70(3):286-299.
33. Pozzi E, Boeri L, Capogrosso P, et al. Infertility as a Proxy of Men’s Health: still a long way to go. Turk J Urol. 2021. Online ahead of print.
34. Tharakan T, Bettocchi C, Carvalho J, et al. European Association of Urology Guidelines Panel on male sexual and reproductive health: a clinical consultation guide on the indications for performing sperm DNA fragmentation testing in men with infertility and testicular sperm extraction in nonazoospermic men. Eur Urol Focus. 2021;8(1):339-350.
35. Agarwal A, Majzoub A, Baskaran S, et al. Sperm DNA fragmentation: a new guideline for clinicians. World J Mens Health. 2020;38(4):412-471.
36. Boeri L, Capogrosso P, Ventimiglia E, et al. High-risk human papillomavirus in semen is associated with poor sperm progressive motility and a high sperm DNA fragmentation index in infertile men. Hum Reprod. 2019;34(2):209-217.
37. Sivanarayana T, Ravi Krishna C, Jaya Prakash G, et al. Sperm DNA fragmentation assay by sperm chromatin dispersion (SCD): correlation between DNA fragmentation and outcome of intracytoplasmic sperm injection. Reprod Med Biol. 2014;13(2):87-94.
38. Muriel L, Meseguer M, Fernández JL, et al. Value of the sperm chromatin dispersion test in predicting pregnancy outcome in intrauterine insemination: a blind prospective study. Hum Reprod. 2006;21(3):738-744.
39. Le MT, Nguyen TAT, Nguyen HTT, et al. Does sperm DNA fragmentation correlate with semen parameters? Reprod Med Biol. 2019;18(4):390-396.
40. Agarwal A, Leisegang K, Majzoub A, et al. Utility of antioxidants in the treatment of male infertility: clinical guidelines based on a systematic review and analysis of evidence. World J Mens Health. 2021;39(2):233-290.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article**: Boeri L, Fallara G, Pozzi E, et al. The impact of different WHO reference criteria for semen analysis in clinical practice: Who will benefit from the new 2021 thresholds for normal semen parameters? Andrology. 2022;10:1134–1142. https://doi.org/10.1111/andr.13213